One event. Multiple sources.
Health

Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

1 publisher first detected 2% of 46 Health publishers

Headline as filed by Medical Xpress.

Compare coverage — 1 report

Every publisher that filed on this event, earliest first, with each one's headline, summary, times and how long after the first report they filed.
Publisher Headline Summary Published Detected Delay Source Status
Medical Xpress Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be pr
0m medicalxpress.com First

Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.

Reader comments

Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.

Nobody has commented on this story yet.

Add a comment

Up to 2,000 characters. Links are not accepted. Blank lines separate paragraphs.

In this story
SGLT 3

Related coverage

connected by shared subjects